1. Generics Bulletin
  2. >>Products

Coherus Confirms Udenyca Launch And Brings In Chief Medical Officer

 
• By Dean Rudge

The California-based biosimilars player has come good on its promise to introduce early in the new year its first biosimilar in the US and the second biosimilar of Amgen’s Neulasta blockbuster; at the same time, biotech veteran Darlene Horton has joined Coherus’ management team.

SiliconValley
Coherus, based in Silicon Valley, has just rolled out Udenyca in the US • Source: Shutterstock

Coherus BioSciences has launched its Udenyca (pegfilgrastim-cbqv) 6mg/0.6ml pre-filled syringes biosimilar to Amgen’s Neulasta in the US, matching the 3 January launch date promised by management upon US Food and Drug Administration (FDA) approval last November.

Days earlier, “biotechnology leader” Darlene Horton joined the California-based player as chief medical and regulatory affairs officer, lauding the “significant opportunity to accelerate

More from Products

More from Generics Bulletin